Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders

Part of paid clinical trials in Ann Arbor, Michigan.

Sponsor
University of Michigan Rogel Cancer Center
Study ID
NCT03601819
Phase
PHASE1
Status
Terminated

Conditions

  • Chronic Lymphocytic Leukemia
  • Lymphoma, T-Cell, Cutaneous
  • Lymphoma, T-Cell, Peripheral
  • Lymphoplasmacytic Lymphoma
  • Lymphoproliferative Disorders
  • Mantle Cell Lymphoma
  • Waldenstrom Macroglobulinemia

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pacritinib — DRUG
    Patients will receive continuous treatment until progressive disease, toxicity, or until any other condition for treatment discontinuation has been met.

Study Details

This trial will determine the safety and tolerability of Pacritinib in patients with relapsed/refractory lymphoproliferative disorders.

Key Dates

Start date
May 15, 2019
Status verified
Jan 2021
Primary completion
Mar 7, 2020
Completion
Jul 17, 2020

Study Design

Enrollment
4 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Pacritinib
    200 mg twice daily (with possible dose reduction to 100 mg twice daily)

Primary Outcome Measure

Rate of dose limiting toxicities (DLT) [ Time Frame: At 28 days ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Michigan Rogel Cancer CenterAnn ArborMichigan48109-

Find similar trials in Ann Arbor, MI

By condition
Leukemia (other)
By specialty
OncologyBlood cancer
By research site
University of Michigan Rogel Cancer Center· Ann Arbor, MI

Related Studies